Aurobindo Pharma Secures USFDA Approval for First MDI Product in US$301M Market
Aurobindo Pharma has received final USFDA approval for Beclomethasone Dipropionate HFA Inhalation Aerosol, marking its entry into the metered-dose inhaler (MDI) segment. The product targets a US market valued at approximately US$301 million and will be manufactured in North Carolina.
Sat Kartar Life to Establish ₹0.70 Cr Hospital-cum-Therapy Centre in Dehradun
Sat Kartar Life Limited has signed a Letter of Intent to establish a 20-bed hospital-cum-therapy centre in Dehradun, Uttarakhand. The project involves an estimated investment of ₹70 Lacs and is part of the company's broader strategy to expand its healthcare delivery network through Ayurveda-based therapies.
Shilpa Medicare Secures SEC Approval for World-First OERIS Long-Acting Injectable
Shilpa Medicare has received final approval from the CDSCO Subject Expert Committee for OERIS, a world-first extended-release ondansetron injection. The product, used for managing chemotherapy-induced nausea, offers five days of protection from a single dose and holds patent security until 2039.
Glenmark Pharmaceuticals Launches RYALTRIS Nasal Spray in Brazil; Targets 60 Million Patients
Glenmark Pharmaceuticals has launched RYALTRIS nasal spray in Brazil for treating moderate to severe allergic rhinitis in patients aged 12 and older. This dual-action therapy, combining an antihistamine and corticosteroid, marks a major expansion into Latin America's largest healthcare market.
Acutaas Chemicals Secures Indian Patent for 2,4-Dimethylthiophenol Process
Acutaas Chemicals Limited has been granted a process patent by the Indian Patent Office for its indigenously developed method to prepare 2,4-dimethylthiophenol. This grant secures exclusive rights for a 20-year term and brings the company's total patent portfolio to 11 specialized processes.
IOLCP Unveils ₹495 Crore Expansion Plan: 50% Ibuprofen Capacity Boost and CDMO Entry
IOL Chemicals and Pharmaceuticals (IOLCP) has initiated a multi-pronged ₹495 crore expansion strategy at its Barnala facility to solidify its global leadership in Ibuprofen and diversify into higher-margin segments. The plan includes a massive 50% capacity hike for its core Ibuprofen product alongside the launch of new CDMO and specialty chemical verticals.
Natco Pharma Board Approves ₹1,300 Crore Rights Issue and Updates Demerger Plan
Natco Pharma's board has authorized a major fund-raising exercise via a rights issue of equity shares worth up to ₹1,300 crore. This capital infusion is intended to strengthen the balance sheet and will lead to a revised demerger scheme for its crop health division to maintain existing swap ratios.
Fermenta Biotech Signs Exclusive Licence with VIT Vellore for Vitamin B12 Technology
Fermenta Biotech Limited has signed an exclusive licence agreement with VIT Vellore for a natural in-situ Vitamin B12 fortification technology. This innovation allows for nutrient enrichment during the fermentation process of staples like curd and dosa batter, targeting widespread dietary deficiencies.
Alkem Laboratories Launches Renocia Exo Patented Hair Growth Serum in India
Alkem Laboratories has announced the launch of Renocia Exo™, a patented hair regeneration therapy utilizing advanced phyto-exosome technology. The product marks a significant expansion of the company's dermatology portfolio, targeting complex biological mechanisms driving hair loss in the Indian market.